Director Steve E. Krognes sold 9,294 shares of GH at $132.51 on 2026-06-04, reducing holdings by 47.6%.
Steve E. Krognes sold approximately half his stake (9,294 of 19,516 shares) at $132.51, which sits within the 52-week range but near the high end (only -6.5% from the $134.28 peak). The stock has gained 37.7% over the past 90 days and 36.2% over the past 30 days, placing the sale near a recent momentum inflection. Guardant Health remains unprofitable on a full-year basis with net income of $-112.1M, despite robust annual revenue growth of 32.9%, creating tension between growth narrative and near-term profitability. The insider's cross-ticker track record shows 1 prior sell with a 90-day well-timed rate of 0.00%, offering limited predictive signal for this transaction's timing quality.